Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.

@article{Abrial2005PathologicalAC,
  title={Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.},
  author={Catherine J Abrial and Isabelle van Praagh and R{\'e}mi Delva and Bernard Leduc and Jo{\"e}l Fleury and Erick Gamelin and Isabelle Sillet-Bach and Fr{\'e}d{\'e}rique Penault-Llorca and Sophie Amat and Philippe Chollet},
  journal={The oncologist},
  year={2005},
  volume={10 4},
  pages={242-9}
}
This phase II study investigated the efficacy and tolerability of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel (VEP protocol) in women with stage II/III operable breast cancer. Patients (n = 50) were treated with six cycles of VEP according to the following schedule: vinorelbine (Navelbine); Pierre Fabre, Boulogne, France; http://www.pierre-fabre.com) 20 mg/m2, epirubicin (Farmorubicin; Pharmacia, New York, NY; http://www.pnu.com) 35 mg/m2 given on days 1 and… CONTINUE READING